Moody National Bank Trust Division Sells 9,508 Shares of Merck & Co., Inc. (NYSE:MRK)

Moody National Bank Trust Division reduced its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 12.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 64,337 shares of the company’s stock after selling 9,508 shares during the period. Merck & Co., Inc. accounts for approximately 0.2% of Moody National Bank Trust Division’s portfolio, making the stock its 27th largest holding. Moody National Bank Trust Division’s holdings in Merck & Co., Inc. were worth $5,279,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MRK. Sheets Smith Wealth Management grew its holdings in shares of Merck & Co., Inc. by 0.5% during the fourth quarter. Sheets Smith Wealth Management now owns 24,741 shares of the company’s stock worth $1,896,000 after purchasing an additional 124 shares in the last quarter. Ritter Daniher Financial Advisory LLC grew its holdings in shares of Merck & Co., Inc. by 33.9% during the fourth quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock worth $40,000 after purchasing an additional 131 shares in the last quarter. First Interstate Bank grew its holdings in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. First Interstate Bank now owns 8,509 shares of the company’s stock worth $653,000 after purchasing an additional 134 shares in the last quarter. Mckinley Capital Management LLC Delaware grew its holdings in shares of Merck & Co., Inc. by 0.9% during the fourth quarter. Mckinley Capital Management LLC Delaware now owns 14,621 shares of the company’s stock worth $1,121,000 after purchasing an additional 135 shares in the last quarter. Finally, Capital City Trust Co. FL grew its holdings in shares of Merck & Co., Inc. by 4.2% during the fourth quarter. Capital City Trust Co. FL now owns 3,376 shares of the company’s stock worth $259,000 after purchasing an additional 137 shares in the last quarter. Institutional investors and hedge funds own 72.88% of the company’s stock.

Shares of Merck & Co., Inc. stock opened at $89.16 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 0.75. The company has a market cap of $225.47 billion, a PE ratio of 15.95, a P/E/G ratio of 1.19 and a beta of 0.36. The business has a 50 day moving average of $88.75 and a 200 day moving average of $82.17. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $94.92.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.81 by $0.33. The company had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The firm’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. On average, research analysts anticipate that Merck & Co., Inc. will post 7.32 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 8th. Shareholders of record on Wednesday, June 15th will be issued a $0.69 dividend. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 49.37%.

Several analysts have issued reports on MRK shares. Morgan Stanley cut their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Barclays upped their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. SVB Leerink reaffirmed an “outperform” rating and issued a $102.00 target price on shares of Merck & Co., Inc. in a research note on Monday, June 6th. Mizuho started coverage on Merck & Co., Inc. in a research note on Friday, April 1st. They issued a “buy” rating and a $100.00 target price for the company. Finally, StockNews.com started coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.60.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.